Vitiligo
Conditions
Interventions
Control Group:Fire Needle
Sponsors
Xinjiang Uyghur Autonomous Region Uyghur Medical Hospital (Xinjiang Uyghur Autonomous Region Second People's Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Consistent with the diagnosis of advanced vitiligo, with a VIDA score of =2 points; (2) Evaluation of the severity of vitiligo: Patients with mild (body surface area =1%), moderate (1%< body surface area <5%), and severe (5%= body surface area <50%); (3) It is in line with the diagnosis of non-segmental (common type) vitiligo, including disseminated type, generalized type and mixed type. (4) Patients diagnosed with astringent and mucous type vitiligo in Uyghur medicine. (5) Age: 18 to 65 years old; (6) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with vitiligo on the fingertips, special areas of the external genitalia, anus, and mucous membranes. (2) Some cases of depigmentation left after the disappearance of certain rashes, such as anemic nevus, albinism, and white patches caused by other syndromes, senile white patches, hypopigmented nevus, solar white patches, etc. (3) Patients with active tuberculosis, advanced malignant tumors, or a history of tumors within 5 years. (4) Combined with severe heart failure, serious primary diseases of the liver, kidney system, etc.(Note: ALT and AST exceed the upper limit of the normal range by twice, and Cr exceeds the upper limit of the normal range.)" (5) Women planning to conceive, those who are pregnant or breastfeeding. (6) Suspected or confirmed history of alcohol or drug abuse. (7) Allergic constitution (to two or more other drugs), or those who are allergic to the drug components or treatment methods in this diagnosis and treatment plan. (8) Those who have other conditions that reduce the possibility of enrollment or complicate enrollment, such as frequently changing working environments, mental disorders, communication difficulties, etc., and whom the researchers consider unsuitable to participate in this clinical trial. (9) There has been a history of using steroids or retinoids in the past two weeks;Those who have participated in or are currently participating in other clinical trials within the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The decline index of the vitiligo Area Score Index (VASI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Quantification Table of Abnormal Body Fluid Quality Typing in Uyghur Medicine for Vitiligo;Vitiligo Visualization Scale (VNS);The condition stability on the 45th day; | — |
Countries
China
Contacts
Public ContactAman GUL
Xinjiang Uyghur Autonomous Region Uyghur Medical Hospital (Xinjiang Uyghur Autonomous Region Second People's Hospital)
Outcome results
None listed